Stock CLBT CELLEBRITE DI LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cellebrite DI Ltd.

Equities

CLBT

IL0011794802

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
10.66 USD +1.33% Intraday chart for Cellebrite DI Ltd. -3.96% +23.09%
May. 24 JPMorgan Adjusts Price Target on Cellebrite DI to $14 From $12, Maintains Overweight Rating MT
May. 24 Deutsche Bank Adjusts Price Target on Cellebrite to $15 From $13, Maintains Buy Rating MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Software

1st Jan change Capi. Investor Rating ESG Refinitiv
CELLEBRITE DI LTD. Stock Cellebrite DI Ltd.
+23.09% 2.19B -
SYNOPSYS INC. Stock Synopsys Inc.
+8.91% 85.92B
B
CADENCE DESIGN SYSTEMS, INC. Stock Cadence Design Systems, Inc.
+5.14% 77.93B
B+
DASSAULT SYSTÈMES SE Stock Dassault Systèmes SE
-16.20% 52.89B
B+
PALANTIR TECHNOLOGIES INC. Stock Palantir Technologies Inc.
+26.18% 48.28B
D+
THE TRADE DESK, INC. Stock The Trade Desk, Inc.
+28.93% 45.38B
D+
ATLASSIAN CORPORATION Stock Atlassian Corporation
-34.05% 40.83B
B-
SEA LIMITED Stock Sea Limited
+66.72% 38.78B
D+
TAKE-TWO INTERACTIVE SOFTWARE, INC. Stock Take-Two Interactive Software, Inc.
-0.36% 27.48B
C+
ROBLOX CORPORATION Stock Roblox Corporation
-26.47% 21.52B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CLBT Stock
  4. Ratings Cellebrite DI Ltd.